HomeBUSINESS
BUSINESS

Opdivo Gains Nod for Gastric Cancer; Spinraza Now Available for All SMA Patients
(Sep.25.2017)

Ono Pharmaceutical and Bristol-Myers Squibb said on September 22 that their PD-1 inhibitor Opdivo (nivolumab) has been approved in Japan for unresectable advanced/recurrent gastric cancer, the sixth indication in the country that could treat 4,600 patients annually ...
(LOG IN FOR FULL STORY)

News Calendar